Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Single-arm Study of Canakinumab in Japanese Patients With Systemic Juvenile Idiopathic Arthritis
jRCT2080222813Phase 3
- Sponsor
- Novartis
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of canakinumab in systemic juvenile idiopathic arthritis (SJIA), sponsored by Novartis.
02
Drugs
canakinumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on jRCT2080222813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222813.